Sign in

Roel Verhaak

@roelverhaak.bsky.social
747 followers 194 following 70 posts

Yale Dpt of Neurosurgery, cancer research, brain tumors, ecDNA, likes football, drums and karaoke.

PostsRepliesMedia
Roel Verhaak @roelverhaak.bsky.social · 27/09/2026
Sunday rainy afternoon drum tuning session.
000
Roel Verhaak @roelverhaak.bsky.social · 08/08/2026
In Bar Harbor for the Jackson Lab cancer course and the views are stunning.
040
Roel Verhaak @roelverhaak.bsky.social · 23/07/2026
We took a deep dive to understand the hereditary component of a family unduly touched by glioblastoma and uncovered a new pathogenic variant. This may reflect a paradigm: highly pathogenic and rare variants may be responsible for familial glioma risk. www.medrxiv.org/content/10.6...
medrxiv.org
Germline Variants in Centromere Binding Protein 126 Predispose to Glioblastoma
Background Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. While only 5% of GBM cases arise in a familial context, the genetic basis of familial GBM remains unresolved i...
050
Roel Verhaak @roelverhaak.bsky.social · 18/07/2026
Worst world cup of all time, ruined by FIFA’s greed.
000
Roel Verhaak @roelverhaak.bsky.social · 25/06/2026
At the Kansas City Oranje fanwalk, it seemed less than 10% were Dutch speaking, serving as an elegant reminder that the US is a country of immigrants.
000
Roel Verhaak @roelverhaak.bsky.social · 23/06/2026
Jumping on the bandwagon and am using Claude to create a 'Karpathy'-style person wiki/LLM. I wonder if it could help expedite manuscript and grant reviews.
000
Reposted by Roel Verhaak
Gaetano Gargiulo @ggargiul.bsky.social · 17/06/2026
We're finalizing the #BTM2026 scientific program and selecting the last short oral presentations. ⏳ Deadline extended: July 1 Join an exceptional international speaker line-up & help shape the discussion on brain tumors! 📍 Berlin | Oct 14–15, 2026 #NeuroOncology #BrainTumors
035
Roel Verhaak @roelverhaak.bsky.social · 04/06/2026
In our new collaborative paper on IDHmutant glioma with the Tirosh, Suva, Iavarone and Lasorella labs, we show how acquired genetic alterations converge with cell state changes and poor treatment responses. www.nature.com/articles/s41...
nature.com
Acquired genetic and cell-state changes in IDH-mutant glioma progression - Nature
Longitudinal transcriptomic, chromatin and genomic analyses of the two types of IDH-mutant glioma reveal in detail how disease progression is influenced by interdependent genetic, epigenetic and micro...
2167
Reposted by Roel Verhaak
Peter Ly @peterlylab.bsky.social · 19/05/2026
Excited to share our latest paper! We found that large pieces of the human genome can transfer between cells upon direct contact, endowing recipient cells with heritable phenotypic changes. @cp-cell.bsky.social (1/7) www.cell.com/cell/fulltex...
1116667
Roel Verhaak @roelverhaak.bsky.social · 19/05/2026
Genome instability triggers intercellular DNA transfer between human cells www.cell.com/cell/fulltex...
cell.com
Genome instability triggers intercellular DNA transfer between human cells
Mammalian cells can pass damaged pieces of their genome directly to neighboring cells via contact-dependent, nanotube-like connections. These transferred DNA fragments persist and function, revealing ...
030
Roel Verhaak @roelverhaak.bsky.social · 01/04/2026
The first funder to see the light, hopefully more will follow! news.cancerresearchuk.org/2026/04/01/w...
news.cancerresearchuk.org
Why we won’t be funding open access publishing any more - Cancer Research UK - Cancer News
The open access movement was bold and promising, but ultimately disappointing. Now is the time to stop and call for a new way to make publishing work…
030
Roel Verhaak @roelverhaak.bsky.social · 26/03/2026
Why, in 2026, do reviewers still have to browse all over the PDF to find figures and figure legends, rather than embedding them with the text. Journals (not the editors!) really do not care about reviewers and their time.
120
Roel Verhaak @roelverhaak.bsky.social · 20/03/2026
Interesting observation on a specific subset of H3-altered gliomas: DNA Methylation Profiling Reveals a Novel Subtype Harboring IDH Mutation in H3-altered Gliomas academic.oup.com/neuro-oncolo...
academic.oup.com
DNA Methylation Profiling Reveals a Novel Subtype Harboring IDH Mutation in H3-altered Gliomas
AbstractBackground. H3-altered gliomas, now recognized by WHO CNS5 as grade 4 neoplasms driven by histone H3 mutations (notably H3K27M and H3G34R/V), exhib
010
Reposted by Roel Verhaak
Curtis Pickering @cpickering.bsky.social · 22/01/2026
There is a lot of talk lately about multi-year funding (MYF) at NIH. This is mostly a paperwork issue, but it can have a dramatic impact on the number of grants that get funded. I was curious how this would impact grant numbers over time, so I did some simple modeling. 1/n
Plot of modeling new NIH grants after a switch to 100% MYF. There is a large drop in grants in the first year with a gradual recovery over 5 years.
22521
Roel Verhaak @roelverhaak.bsky.social · 22/01/2026
Raise your hand if you think that the new biosketch formatting will improve the ways NIH distributes extramural funding or funding transparency.
010
Roel Verhaak @roelverhaak.bsky.social · 20/01/2026
Having too much with the new wired birdfeeder and its AI powered bird recognition feature. Its a dark-eyed junco!
040
Reposted by Roel Verhaak
Harmit Singh Malik @harmitmalik.bsky.social · 18/12/2025
I can't believe this still needs to be said (and more loudly): Trans rights are human rights.
418546
Reposted by Roel Verhaak
Mustafa Khasraw @mkhasraw.bsky.social · 06/12/2025
And here is your accompanying editorial: Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development url: academic.oup.com/neuro-oncolo...
academic.oup.com
Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development
Julia Louw, Jodie Jepson, Anna M Corcoran, Mustafa Khasraw; Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development, N
052
Reposted by Roel Verhaak
Anna Golebiewska @annagolebiewska.bsky.social · 23/11/2025
Happy to share a new #NORLUX study on how humanized patient-derived xenografts of #glioblastoma can be useful in investigating immunosuppression and clinically-relevant immunotherapy testing. See for more: www.biorxiv.org/content/10.1... #immunotherapy, #preclinicalmodeling,
0154
Reposted by Roel Verhaak
Eunhee Yi @eunhee-yi.bsky.social · 20/11/2025
It was a great pleasure to learn about a recent discovery in ecDNA biology that answers the most critical question on ecDNA maintenance! @nature.com Are you a non-scientist? No worries! My team wrote a lay-audience-friendly summary about this exciting research finding! Check it out! rdcu.be/eQMvM
rdcu.be
Circular DNA has a ticket to ride chromosomes | Nature
How circular extrachromosomal DNA is inherited during cell division is a puzzle. Key sequences enabling this DNA to journey with chromosomes have been identified. How circular extrachromosomal DNA is inherited during cell division is a puzzle. Key sequences enabling this DNA to journey with chromosomes have been identified.
094
Reposted by Roel Verhaak
Shwetal Mehta @shwetalm.bsky.social · 08/11/2025
Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social
061
Roel Verhaak @roelverhaak.bsky.social · 08/11/2025
Delighted to share this new collaborative paper with the Ivy BTC where we performed deep characterization of glioma patients enrolled on a CDK4/6i Phase 0 trial academic.oup.com/neuro-oncolo... with @kevin-johnson.bsky.social @shwetalm.bsky.social @nadersanai.bsky.social
academic.oup.com
Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
AbstractBackground. Outcomes for adult patients with high-grade glioma (HGG) remain poor, necessitating new treatment strategies. Key challenges include po
081
Reposted by Roel Verhaak
David Shiffman, Ph.D. 🦈 @whysharksmatter.bsky.social · 30/10/2025
Sharks absolutely get cancer, and people claiming otherwise are pseudoscientific grifters preying on the desperate. Even if sharks did not get cancer, eating shark would not cure your cancer any more than eating LeBron James would make you better at basketball.
611213296
Reposted by Roel Verhaak
Mustafa Khasraw @mkhasraw.bsky.social · 29/10/2025
Senior Research Tech (Duke) – tumor immunobiology lab. Work with tumor/blood/CSF samples, culture patient-derived cell lines, assist single-cell assays, and support & lead research. Bio degree + research exp required. No visa sponsorship. Title may vary. Apply → careers.duke.edu/job-invite/2...
careers.duke.edu
RESEARCH TECHNICIAN III
RESEARCH TECHNICIAN III
012
Reposted by Roel Verhaak
Broad Institute @broadinstitute.org · 16/10/2025
A new drug candidate for a difficult-to-treat type of lung cancer, developed by scientists in the Broad-Bayer oncology research alliance, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.
broadinstitute.org
Broad-Bayer collaboration leads to drug candidate for a hard-to-treat type of lung cancer
The compound, now under priority review at FDA, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.
072
Reposted by Roel Verhaak
Michael Platten, MD @michael-platten.bsky.social · 04/10/2025
The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/... Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.
science.org
The immunology of brain tumors
The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.
02511
Roel Verhaak @roelverhaak.bsky.social · 16/09/2025
Today’s lab meeting is a debate of recent Nature/Science retraction decisions: fair or not? Important lesson that not all retractions are the same, authors not always to blame.
160
Reposted by Roel Verhaak
Sarah Aitken @s-j-aitken.bsky.social · 22/08/2025
Almost half way to our fundraising target - and only two weeks to go! I'll be riding the 100 mile #CloserToFreeRide to raise money to support cancer research and patient care. Please consider donating - every penny counts! ➡️ www.rideclosertofree.org/participants... #CTFRide @ctfride.bsky.social
rideclosertofree.org
A fundraising page for Sarah Aitken
Join the Closer to Free Ride on Saturday, September 6th. Register or donate at RideCloserToFree.org.
011
Reposted by Roel Verhaak
Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · 19/08/2025
Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children. These children need MORE funding and MORE trials, not less. They deserve better
21815
Reposted by Roel Verhaak
Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 19/08/2025
🔥 Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social @neuroonc.bsky.social
academic.oup.com
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
Abstract. Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Orga
032
Reposted by Roel Verhaak
Yale Cancer Center @yalecancer.bsky.social · 12/08/2025
Findings from @roelverhaak.bsky.social et al. reveal lentiviral transduction + antibiotic selection dramatically ⬇️ ecDNA+ #cancer cells, revealing both a challenge for research and a potential therapeutic clue. #ecdna aacrjournals.org/cancerrescom... @aacrjournals.bsky.social
aacrjournals.org
Selective depletion of cancer cells with extrachromosomal DNA via lentiviral infection
Abstract. Extrachromosomal DNA (ecDNA), a major focal oncogene amplification mode found across cancer, has recently regained attention as an emerging cancer hallmark, with a pervasive presence across ...
022
Roel Verhaak @roelverhaak.bsky.social · 12/08/2025
Happy to provide a comment on recent work by the Maciejowski lab on ecDNA inheritance www.cell.com/molecular-ce... and authors.elsevier.com/a/1lZPK3vVUP... - with Xue Jin
authors.elsevier.com
160
Reposted by Roel Verhaak
Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · 31/07/2025
Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org rdcu.be/eyHcG
rdcu.be
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...
141
Roel Verhaak @roelverhaak.bsky.social · 23/07/2025
PO just confirmed that our 5th percentile R01 is not getting funded. Past NCI Payline at 4 percent. Cant believe it.
2018489
Reposted by Roel Verhaak
Trevor Graham @trevorgraham.bsky.social · 17/07/2025
Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team
nature.com
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature
A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...
03112
Roel Verhaak @roelverhaak.bsky.social · 16/07/2025
New preprint on longitudinal treatment response signatures in IDH-mutant glioma from the GLASS Consortium www.biorxiv.org/content/10.1...
biorxiv.org
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas
Astrocytomas and oligodendrogliomas are slow-growing and treatment-sensitive IDH-mutant gliomas diagnosed at ages 30-50. Local tumor regrowth and treatment resistance is inevitable resulting in 3-10 y...
2214
Reposted by Roel Verhaak
Sarah Aitken @s-j-aitken.bsky.social · 27/06/2025
Together with friends and colleagues from #CMCO @yalecancer.bsky.social, @yalepathology.bsky.social, and further afield, we are the #CycloPaths Closer to Free Ride 🚲06 September 2025 💪100 miles #CTFRide Join our team, spread the word, sponsor us if you can www.rideclosertofree.org/participants...
rideclosertofree.org
A fundraising page for Sarah Aitken
Join the Closer to Free Ride on Saturday, September 6th. Register or donate at RideCloserToFree.org.
181
Roel Verhaak @roelverhaak.bsky.social · 27/06/2025
After three days of engaged discussions, we wrapped up the 2025 Mark Foundation on Genomic Instability. What a fun event with amazing participants.
Group photo of workshop participants
140
Reposted by Roel Verhaak
The Mark Foundation for Cancer Research @themarkfdn.bsky.social · 24/06/2025
It's 102°F/39°C in New Haven—but 30 international experts have braved the heatwave to join us at @yaleschoolofmed.bsky.social for a 3-day workshop on chromosomal instability in cancer. Thank you to our workshop organizers @roelverhaak.bsky.social, Florian Markowetz, & Aurelie Ernst!
041
Roel Verhaak @roelverhaak.bsky.social · 24/06/2025
Excited to host nearly 30 international experts for the @themarkfdn.bsky.social workshop on genomic instability in cancer at @yaleschoolofmed.bsky.social today! This area of research is ready for the next breakthrough. @yalecancer.bsky.social
051
Reposted by Roel Verhaak
Nicolas Robine 🇪🇺🇫🇷🇺🇸 @nicorobine.bsky.social · 18/06/2025
Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas www.nature.com/articles/s41...
nature.com
Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas - Nature Communications
Currently, there is limited knowledge about the spatial heterogeneity of glioma-driving molecular events. Here, the authors employ a multiomics approach to characterize the spatial transcriptomic hete...
011
Reposted by Roel Verhaak
Yale Cancer Center @yalecancer.bsky.social · 27/05/2025
.@roelverhaak.bsky.social: “We’re recognizing that we need a paradigm shift – that we need to approach the disease [#braincancer] differently than we have so far.” yalecancercenter.org/news-article... @theaacr.bsky.social #NCRM25 #unitedbycancerresearch #btsm
yalecancercenter.org
'Paradigm Shift' in Brain Cancer Research Needed, Says Yale Professor
Researchers need to find solutions differently than in the past to break through with treatments for aggressive brain cancers.
051
Reposted by Roel Verhaak
Kadir Akdemir @kcakdemir.bsky.social · 22/05/2025
Excited to share our latest manuscript www.biorxiv.org/content/10.1... This was a great collaboration with Drs. Huse, Lang, @jesserdixon.bsky.social
1156
Reposted by Roel Verhaak
Remco van de Pas @rvandepas.bsky.social · 16/05/2025
Indigenous West Papuans claim Indonesian government is 'land grabbing' www.rnz.co.nz/internationa... West Papuans in Merauke claim the Indonesian government is stealing land to build its global "food barn" and feed its population of 280 million.
rnz.co.nz
Indigenous West Papuans claim Indonesian government is 'land grabbing'
But Indonesia denies this, saying all land sales transactions are lawful and "there is no land grab without consent".
021
Reposted by Roel Verhaak
Avishay Spitzer, MD, PhD @avishayspitzer.bsky.social · 10/05/2025
1/ Truly excited to share our new study that I had to privilege to co-lead during my PhD alongside great friends and collaborators @masashi-nomura.bsky.social, @kevin-johnson.bsky.social and Luciano Garofano, published at Nature Genetics @natureportfolio.nature.com! www.nature.com/articles/s41...
nature.com
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics - Nature Genetics
Comparison of paired primary and recurrent glioblastomas at the single-cell transcriptomic level describes molecular and cellular trajectories associated with tumor recurrence, highlighting extensive ...
33415
Reposted by Roel Verhaak
Masashi Nomura @masashi-nomura.bsky.social · 09/05/2025
1/ Thrilled to share our TWO back-to-back papers published in Nature Genetics today! www.nature.com/articles/s41... , www.nature.com/articles/s41...
nature.com
The multilayered transcriptional architecture of glioblastoma ecosystems - Nature Genetics
Integrated single-cell transcriptomic and genetic characterization of 121 adult glioblastomas identifies heterogeneity at cell type, cell state and baseline expression program levels associated with s...
124216
Roel Verhaak @roelverhaak.bsky.social · 03/05/2025
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors www.cell.com/cell/abstrac...
cell.com
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors
This study demonstrates that extrachromosomal DNA (ecDNA) replication induces DNA double-strand breaks and activates the DNA damage response (DDR). The DDR pathways, such as alt-NHEJ, are critical for...
060
Roel Verhaak @roelverhaak.bsky.social · 26/04/2025
I have never seen a conference session as oversubscribed as the Next-gen ADC session. Even the overflow room is overflowing. Clearly a flaming hot topic. #AACR25
030
Roel Verhaak @roelverhaak.bsky.social · 25/04/2025
I look forward to the educational session on ecDNA, Sat 1230p-2p in room S403 #AACR #AACR25
062
Roel Verhaak @roelverhaak.bsky.social · 24/04/2025
Well worded arguments why investment in biotech science is a no-brainer www.amjmed.com/article/S000...
amjmed.com
Killing the Science Golden Goose
In the 1970’s I was probably one of the last American high school students who was told that if you wanted to go to medical school, you should learn to speak German. This was because in the late 19th ...
000